Lumito AB
NNGM:LUMITO0.55
SEK
+0.15
(+36.63%)
ISIN
SE0027620956
Return %
Stock
S&P 500
1Y
-96.64
14.20
3Y
-99.69
81.12
5Y
-99.71
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sanna Wallenborg
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lund Sweden
- IPO Date
- Oct 19, 2018
- Website
- lumito.se
- Similar Companies
- Business
- Lumito AB is a Sweden-based medical technology and digital pathology company that develops and commercializes optical imaging systems and diagnostic solutions for preclinical research, translational medicine, and clinical pathology. Founded in 2010 as a spin-out from Lund University and headquartered in Lund, Sweden, the company utilizes patented Upconverting Nanoparticle (UCNP) technology and pulsed laser illumination to eliminate background tissue autofluorescence and enable high-contrast, quantitative biomarker analysis. The company's product and service portfolio includes the SCIZYS digital pathology scanner, an optical imaging platform designed for whole-slide analysis and sensitive detection of nanoparticle markers; SCIZYS Reagent Kits, featuring proprietary nanoparticle-conjugated antibody solutions for immunohistochemical (IHC) tissue staining; proprietary image analysis software for automated biomarker quantification and digital workflow integration; and technical support, custom assay development, and laboratory staining services for biomedical researchers and pathology facilities. Lumito AB serves biopharmaceutical corporations, contract research organizations (CROs), academic research centers, and hospital pathology departments across the Nordic region and broader European markets. In recent developments, the company has advanced the commercial launch of its SCIZYS platform and reagent consumables under Research Use Only (RUO) designations, established strategic research and distribution collaborations with European academic medical centers, initiated regulatory validation pathways toward In Vitro Diagnostic Regulation (IVDR) clinical certification, completed equity rights offerings to fund commercial expansion and supply-chain scaling, and expanded its intellectual property portfolio across key international jurisdictions.